skip to main content
Idioma:
Refinado por: Nome da Publicação: Blood remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
KMT2E-Mediated Epigenetic Reprogramming Promotes the Sensitivity to All-Trans Retinoic Acid and Increases the Granulocytic Differentiation in AML Cells
KMT2E-Mediated Epigenetic Reprogramming Promotes the Sensitivity to All-Trans Retinoic Acid and Increases the Granulocytic Differentiation in AML Cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

KMT2E-Mediated Epigenetic Reprogramming Promotes the Sensitivity to All-Trans Retinoic Acid and Increases the Granulocytic Differentiation in AML Cells

Almeida, Luciana Yamamoto ; Weinhäuser, Isabel ; Pereira-Martins, Diego Antonio ; Schiavinato, Josiane Lilian ; Palma, Patrícia Vianna Bonini ; Bonaldo, Camila ; Silva, Cleide Lucia ; Poltronieri, Juliana Oliveira ; Cândido, Larissa ; Lucena-Araujo, Antonio R. ; Rego, Eduardo Magalhães

Blood, 2018-11, Vol.132 (Supplement 1), p.3838-3838 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
2
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Kumar, Shaji K. ; LaPlant, Betsy R. ; Reeder, Craig B. ; Roy, Vivek ; Halvorson, Alese E. ; Buadi, Francis ; Gertz, Morie A. ; Bergsagel, P. Leif ; Dispenzieri, Angela ; Thompson, Melanie A. ; Crawley, Jamie ; Kapoor, Prashant ; Mikhael, Joseph ; Stewart, Keith ; Hayman, Suzanne R. ; Hwa, Yi L. ; Gonsalves, Wilson ; Witzig, Thomas E. ; Ailawadhi, Sikander ; Dingli, David ; Go, Ronald S. ; Lin, Yi ; Rivera, Candido E. ; Rajkumar, S. Vincent ; Lacy, Martha Q.

Blood, 2016-11, Vol.128 (20), p.2415-2422 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Cortes, Jorge ; Lipton, Jeff H. ; Rea, Delphine ; Digumarti, Raghunadharao ; Chuah, Charles ; Nanda, Nisha ; Benichou, Annie-Claude ; Craig, Adam R. ; Michallet, Mauricette ; Nicolini, Franck E. ; Kantarjian, Hagop

Blood, 2012-09, Vol.120 (13), p.2573-2580 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível

Citações Citado por
4
Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study
Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

Ayed, Ayed O. ; Pederson, Levi ; Macon, William R. ; Laplant, Betsy R. ; Reeder, Craig B. ; Foran, James M. ; Nelson, Garth ; Rivera, Candido E. ; Habermann, Thomas M. ; Witzig, Thomas E. ; Nowakowski, Grzegorz S.

Blood, 2016-12, Vol.128 (22), p.5322-5322 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib
Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Kumar, Shaji K ; Laplant, Betsy R. ; Reeder, Craig B. ; Roy, Vivek ; Buadi, Francis ; Gertz, Morie A. ; Laumann, Kristina ; Bergsagel, Peter Leif ; Dispenzieri, Angela ; Kapoor, Prashant ; Mikhael, Joseph ; Stewart, Keith ; Hayman, Suzanne R. ; Hwa, Yi L. ; Witzig, Thomas E. ; Ailawadhi, Sikander ; Dingli, David ; Go, Ronald S. ; Lin, Yi ; Rivera, Candido E. ; Rajkumar, S. Vincent ; Lacy, Martha Q.

Blood, 2015-12, Vol.126 (23), p.3050-3050 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Paulus, Aneel ; Advani, Pooja ; Laplant, Betsy R. ; Akhtar, Sharoon ; Sher, Taimur ; Rivera, Candido E. ; Foran, James M. ; Roy, Vivek ; Colon-Otero, Gerardo ; Ailawadhi, Sikander ; Chanan-Khan, Asher Alban

Blood, 2015-12, Vol.126 (23), p.5299-5299 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
7
Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome
Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome
Material Type:
Artigo 		Adicionar ao Meu Espaço

Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome

Maciejewski, Jaroslaw P. ; Follmann, Dean ; Nakamura, Ryotaro ; Saunthararajah, Yogen ; Rivera, Candido E. ; Simonis, Toni ; Brown, Kevin E. ; Barrett, John A. ; Young, Neal S.

Blood, 2001-12, Vol.98 (13), p.3513-3519 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível

Citações Citado por
8
Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs
Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs
Material Type:
Artigo 		Adicionar ao Meu Espaço

Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs

Paulus, Aneel ; Chitta, Kasyapa S. ; Akhtar, Sharoon ; Kuranz, Maja ; Kumar, Shaji ; Roy, Vivek ; Ansell, Stephen M. ; Mikhael, Joseph R. ; Dispenzieri, Angela ; Reeder, Craig ; Rivera, Candido E. ; Foran, James M. ; Buadi, Francis ; Rajkumar, Vincent ; Chanan-Khan, Asher

Blood, 2013-11, Vol.122 (21), p.1928-1928 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
9
In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation
In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation
Material Type:
Artigo 		Adicionar ao Meu Espaço

In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation

Takahashi, Yoshiyuki ; McCoy, J. Philip Jr ; Carvallo, Cristian ; Rivera, Candido ; Igarashi, Takehito ; Srinivasan, Ramaprasad ; Young, Neal S. ; Childs, Richard W.

Blood, 2004-02, Vol.103 (4), p.1383-1390 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível

Citações Citado por
10
Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study
Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

Nowakowski, Grzegorz S. ; LaPlant, Betsy R. ; Reeder, Craig ; Foran, James M. ; Porrata, Luis F. ; Macon, William R ; Johnston, Patrick B. ; Rivera, Candido E. ; Habermann, Thomas M ; Inwards, David J. ; Micallef, Ivana N. ; Nelson, Garth D ; Ansell, Stephen M. ; Witzig, Thomas E.

Blood, 2012-11, Vol.120 (21), p.689-689 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.